Pazopanib demonstrated activity in prolonging progression-free survival for advanced extrapancreatic neuroendocrine tumors. However, it was associated with an increased rate of severe adverse events and more deaths compared to placebo, highlighting toxicity challenges.
Study
|
Randomized, double-blind, phase II study [Alliance A021202] |
| Advanced, low- to intermediate-grade extrapancreatic neuroendocrine tumors |
| Pazopanib (n=97) vs Placebo (n=74)
|
Efficacy
|
mPFS: 11.8 mos vs 7.6 mos (pazopanib vs. placebo) (HR 0.54 [0.37-0.79]) |
| OS @ 2yrs: 64.4% vs. 66.3%
|
Safety
|
Grade >=3 AE: 84% vs 47% |
| Grade 5 death events: 8% vs 0%
|
J Clin Oncol 2025;43(24):3170-3183
Bergsland EK, Geyer S, Asmis TR New Reference: Pazopanib for Extrapancreatic Neuroendocrine Tumors
http://doi.org/10.1200/JCO-24-02644
Reviewed by Ulas D. Bayraktar, MD on Nov 13, 2025
